title: Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients.
abstract: OBJECTIVE
  Several studies have suggested that phosphodiesterase type 5 inhibitors (5-PDEi) show a potential therapeutic use in the treatment of overactive bladder (OAB) and male lower urinary tract symptoms (LUTS). The aim of this study was to evaluating the efficacy on OAB symptoms, impact on quality of life and sexual function of tadalafil 5mg once daily in older patients versus fesoterodine 8 mg.
  
  
  METHODS
  108 consecutive patients diagnosed with OAB were divided into 2 groups: Group A: 56 patients treated with tadalafil 5 mg once daily; Group B: 52 patients treated with fesoterodine 8 mg, both groups treated for a period of 12 weeks. Eligible patients were men aged ≥ 65 years with OAB symptoms, including urgency and increased frequency during a period of ≥ 1 year and urgency urinary incontinence during a period of ≥ 6 months before enrolment. Patients were asked to complete the 3-day voiding diary prior each scheduled visit at weeks 0, 4 and 12. During these visits, they were administered: Overactive Bladder Symptom Score (OABSS), International Prostate Symptoms Score (IPSS), International Index of Erectile Function (IIEF-5) and Quality of life (QoL).
  
  
  RESULTS
  Not statistically significant differences emerged between the two groups at baseline, both patient groups had similar age and BMI; in each treatment group, the proportion of men ≥ 75 years was approximately 65%. From the results of our study, we can say that a treatment once a day with tadalafil improves not only significantly: micturition/24 hours (p < 0.001), urgency episodes/24 hours (p < 0.003), and urge incontinence episodes (p < 0.001) compared to fesoterodine treatment, but also the quality of life (p < 0.001) and sexual function (p < 0.001) in older patients.
  
  
  CONCLUSIONS
  These analyses demonstrate that tadalafil 5 mg once daily vs. fesoterodine 8 mg is efficacious in the treatment of the symptoms of OAB in older adults, improving also the quality of life and sexual and social life.
authors.affiliation: Department of Urology, University Hospital "S. Anna", Ferrara, Italy. dellatti@hotmail.com.
authors.forename: L
authors.initials: L
authors.lastname: Dell'Atti
mesh_terms: D000368:Aged; D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011788:Quality of Life; D000068581:Tadalafil / Q000008:administration & dosage* / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D064804:Urological Agents / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D001559:Benzhydryl Compounds; D058986:Phosphodiesterase 5 Inhibitors; D064804:Urological Agents; C526675:fesoterodine; D000068581:Tadalafil